Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Baxter

This article was originally published in The Gray Sheet

Executive Summary

Baxter: Standard & Poor's revises its "CreditWatch implications" on Baxter's "single A-minus" long-term debt rating and "A-2" commercial paper rating to "positive" from "developing." The revision also applies to unsecured debt ratings for related entities American Hospital Supply Corp., American Hospital Supply Finance Corp., and Baxter Travenol Laboratories. "If the divestiture of its distribution and surgical products business, Allegiance Corp., is completed as currently planned, the long-term debt and commercial paper ratings will be raised to `single A' and `A-1,' respectively," S&P says, noting that the new ratings "will reflect Baxter's strong positions in four specialty medical product markets and its moderate use of debt financing, offset by management's willingness to achieve growth through large acquisitions"...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts